Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10385)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
CD36
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Responsed Disease | Cardiomyopathy | ICD-11: BC43 | |||
Responsed Drug | Astragaloside IV | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
CHO-S/H9C2 cells | Normal | Cricetulus griseus | CVCL_A0TS | |
In Vivo Model |
Male Sprague-Dawley (SD) rats (160-180 g) were purchased from the Experimental Animal Center of Guangzhou University of Chinese Medicine. After 1 week of acclimatization, the rats were randomly divided into two groups: the control group (standard diet,n = 6) and the high-fat diet (HFD) group. The control group was given a standard diet for 8 weeks, and the HFD group was given a high-fat diet (feed item No. D12451, Guangdong Medical Laboratory Animal Center) for 8 weeks. Subsequently, intraperitoneal injection of streptozotocin (STZ, 40 mg/kg) was performed in the HFD group for inducing diabetic symptoms, and an equal volume of saline was given to the control group. A diabetes model was successfully established under the condition that the fasting blood glucose levels were > 16.7 mmol/L over three consecutive days. Diabetic rats in the HFD group were divided into five groups: a DCM group, three AS-IV treatment groups (20, 40, and 80 mg/kg/day by gavage,n = 6), and an atorvastatin treatment group (ALE group, used as a positive control drug, 10 mg/kg, by gavage,n = 6). Rats were given the standard diet during drug gavage. After 12 weeks of treatment, all animals were anesthetized and then euthanized by intraperitoneal injection with an overdose of pentobarbital sodium. The animal experiments in this study were randomized and single-blind.
Click to Show/Hide
|
||||
Response regulation | Astragaloside IV decreased cardiomyocyte injury and myocardial dysfunction by inhibiting ferroptosis mediated by CD36 in diabetic cardiomyopathy rats. Therefore, AS-IV regulated the lipid metabolism of cardiomyocytes and inhibited cellular ferroptosis, which may have potential clinical value in DCM treatment. | ||||
Cardiomyopathy [ICD-11: BC43]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Platelet glycoprotein 4 (CD36) | Protein coding | |||
Responsed Drug | Astragaloside IV | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
CHO-S/H9C2 cells | Normal | Cricetulus griseus | CVCL_A0TS | |
In Vivo Model |
Male Sprague-Dawley (SD) rats (160-180 g) were purchased from the Experimental Animal Center of Guangzhou University of Chinese Medicine. After 1 week of acclimatization, the rats were randomly divided into two groups: the control group (standard diet,n = 6) and the high-fat diet (HFD) group. The control group was given a standard diet for 8 weeks, and the HFD group was given a high-fat diet (feed item No. D12451, Guangdong Medical Laboratory Animal Center) for 8 weeks. Subsequently, intraperitoneal injection of streptozotocin (STZ, 40 mg/kg) was performed in the HFD group for inducing diabetic symptoms, and an equal volume of saline was given to the control group. A diabetes model was successfully established under the condition that the fasting blood glucose levels were > 16.7 mmol/L over three consecutive days. Diabetic rats in the HFD group were divided into five groups: a DCM group, three AS-IV treatment groups (20, 40, and 80 mg/kg/day by gavage,n = 6), and an atorvastatin treatment group (ALE group, used as a positive control drug, 10 mg/kg, by gavage,n = 6). Rats were given the standard diet during drug gavage. After 12 weeks of treatment, all animals were anesthetized and then euthanized by intraperitoneal injection with an overdose of pentobarbital sodium. The animal experiments in this study were randomized and single-blind.
Click to Show/Hide
|
||||
Response regulation | Astragaloside IV decreased cardiomyocyte injury and myocardial dysfunction by inhibiting ferroptosis mediated by CD36 in diabetic cardiomyopathy rats. Therefore, AS-IV regulated the lipid metabolism of cardiomyocytes and inhibited cellular ferroptosis, which may have potential clinical value in DCM treatment. | ||||
Astragaloside IV
[Investigative]
In total 1 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | ||||
Drug for Ferroptosis | Suppressor | ||||
Response Target | Unspecific Target | ||||
Responsed Disease | Cardiomyopathy | ICD-11: BC43 | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
CHO-S/H9C2 cells | Normal | Cricetulus griseus | CVCL_A0TS | |
In Vivo Model |
Male Sprague-Dawley (SD) rats (160-180 g) were purchased from the Experimental Animal Center of Guangzhou University of Chinese Medicine. After 1 week of acclimatization, the rats were randomly divided into two groups: the control group (standard diet,n = 6) and the high-fat diet (HFD) group. The control group was given a standard diet for 8 weeks, and the HFD group was given a high-fat diet (feed item No. D12451, Guangdong Medical Laboratory Animal Center) for 8 weeks. Subsequently, intraperitoneal injection of streptozotocin (STZ, 40 mg/kg) was performed in the HFD group for inducing diabetic symptoms, and an equal volume of saline was given to the control group. A diabetes model was successfully established under the condition that the fasting blood glucose levels were > 16.7 mmol/L over three consecutive days. Diabetic rats in the HFD group were divided into five groups: a DCM group, three AS-IV treatment groups (20, 40, and 80 mg/kg/day by gavage,n = 6), and an atorvastatin treatment group (ALE group, used as a positive control drug, 10 mg/kg, by gavage,n = 6). Rats were given the standard diet during drug gavage. After 12 weeks of treatment, all animals were anesthetized and then euthanized by intraperitoneal injection with an overdose of pentobarbital sodium. The animal experiments in this study were randomized and single-blind.
Click to Show/Hide
|
||||
Response regulation | Astragaloside IV decreased cardiomyocyte injury and myocardial dysfunction by inhibiting ferroptosis mediated by CD36 in diabetic cardiomyopathy rats. Therefore, AS-IV regulated the lipid metabolism of cardiomyocytes and inhibited cellular ferroptosis, which may have potential clinical value in DCM treatment. | ||||